Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment.
Twenty-six patients with advanced prostatic carcinoma refractory to conventional endocrine treatment were treated with a new oral nonsteriodal antiandrogen, flutamide. There were 6 responders and 20 failures. No serious toxicity attributable to flutamide was observed.
D000368:Aged; D000813:Anilides / Q000627:therapeutic use*; D002369:Castration; D004967:Estrogens / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013997:Time Factors
D000813:Anilides; D004967:Estrogens; D005485:Flutamide